These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 16462177)

  • 1. Donor leukocyte infusions after unrelated donor hematopoietic stem cell transplantation.
    Loren AW; Porter DL
    Curr Opin Oncol; 2006 Mar; 18(2):107-14. PubMed ID: 16462177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation.
    Saito TI; Rubio MT; Sykes M
    Exp Hematol; 2006 Sep; 34(9):1271-7. PubMed ID: 16939820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
    Xia G; Truitt RL; Johnson BD
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.
    Orti G; Lowdell M; Fielding A; Samuel E; Pang K; Kottaridis P; Morris E; Thomson K; Peggs K; Mackinnon S; Chakraverty R
    Transplantation; 2009 Dec; 88(11):1312-8. PubMed ID: 19996931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): study of toxicity and efficacy].
    Michallet AS; Nicolini F; Michallet M
    Bull Cancer; 2003; 90(8-9):758-62. PubMed ID: 14609766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor leukocyte infusions in myeloid malignancies: new strategies.
    Porter DL; Antin JH
    Best Pract Res Clin Haematol; 2006; 19(4):737-55. PubMed ID: 16997180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving immune reconstitution while preventing GvHD in allogeneic stem cell transplantation.
    André-Schmutz I; Dal Cortivo L; Fischer A; Cavazzana-Calvo M
    Cytotherapy; 2005; 7(2):102-8. PubMed ID: 16040389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic transplantation for myelodysplastic syndrome (MDS).
    Ingram W; Lim ZY; Mufti GJ
    Blood Rev; 2007 Mar; 21(2):61-71. PubMed ID: 16759774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion.
    Porter D; Levine JE
    Semin Hematol; 2006 Jan; 43(1):53-61. PubMed ID: 16412789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Donor leukocyte infusion after allogeneic stem cell transplantation].
    de Lacerda JF
    Acta Med Port; 1999; 12(7-11):255-64. PubMed ID: 10707463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia.
    Moore J; Nivison-Smith I; Goh K; Ma D; Bradstock K; Szer J; Durrant S; Schwarer A; Bardy P; Herrmann R; Dodds A
    Biol Blood Marrow Transplant; 2007 May; 13(5):601-7. PubMed ID: 17448920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partially matched related hematopoietic stem cell transplantation without ex vivo T cell depletion compared with matched unrelated transplantation in adult patients with hematologic malignancies.
    Wang Y; Chen F; Han Y; Fu ZZ; Tang XW; Miao M; Qiu HY; Jin ZM; Sun AN; Wu DP
    Biol Blood Marrow Transplant; 2009 Oct; 15(10):1258-64. PubMed ID: 19747633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable long-term survival after bone marrow versus peripheral blood progenitor cell transplantation from matched unrelated donors in children with hematologic malignancies.
    Meisel R; Laws HJ; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Schmitz M; Fischer J; Göbel U; Enczmann J; Dilloo D
    Biol Blood Marrow Transplant; 2007 Nov; 13(11):1338-45. PubMed ID: 17950920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program.
    Kato K; Kanda Y; Eto T; Muta T; Gondo H; Taniguchi S; Shibuya T; Utsunomiya A; Kawase T; Kato S; Morishima Y; Kodera Y; Harada M;
    Biol Blood Marrow Transplant; 2007 Jan; 13(1):90-9. PubMed ID: 17222757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia.
    Elliott MA; Tefferi A; Hogan WJ; Letendre L; Gastineau DA; Ansell SM; Dispenzieri A; Gertz MA; Hayman SR; Inwards DJ; Lacy MQ; Micallef IN; Porrata LF; Litzow MR
    Bone Marrow Transplant; 2006 Jun; 37(11):1003-8. PubMed ID: 16604096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell therapy after hematopoietic stem cell transplantation.
    Kennedy-Nasser AA; Brenner MK
    Curr Opin Hematol; 2007 Nov; 14(6):616-24. PubMed ID: 17898565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human leukocyte antigen DR15 is associated with reduced relapse rate and improved survival after human leukocyte antigen-identical sibling hematopoietic stem cell transplantation.
    Stern M; Passweg J; Tiercy JM; Genitsch A; Meyer-Monard S; Heim D; Tichelli A; Gratwohl A; Nissen-Druey C
    Biol Blood Marrow Transplant; 2006 Nov; 12(11):1169-75. PubMed ID: 17085310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.